Home/Pipeline/CYT-108

CYT-108

Osteoarthritis

Phase 2Active

Key Facts

Indication

Osteoarthritis

Phase

Phase 2

Status

Active

Company

Cytonics

About Cytonics

Cytonics is pioneering a novel therapeutic approach for osteoarthritis, a condition with no approved disease-modifying drugs. The company's platform is centered on engineering the A2M protein, a broad-spectrum protease inhibitor, to create biologics that simultaneously target multiple enzymes responsible for cartilage breakdown. Its lead program, CYT-108, is in FDA clinical trials and represents a potential first-in-class therapy. The company positions itself as a disruptor to Big Pharma's traditional single-target drug development model and emphasizes a community-focused ownership structure.

View full company profile

Therapeutic Areas

Osteoarthritis Musculoskeletal Disorders

Other Osteoarthritis Drugs

Drug	Company	Phase	Status
MSC‑OA	Advancells	Phase 1	Active
Osteoarthritis program	Risen Pharma Tech	Clinical (China & US)	Active
ViscoCell™ for Osteoarthritis	Likarda	Pre-clinical	Active
Osteoarthritis Biologic Therapy	Ageless Biotech	Phase 2b	Active
PKM-011	PK MED	Pre-clinical	Active
Topical PSGAG	ADORA Life Science	Pre-clinical	Active
FGF18 Gene Therapy	Remedium Bio	Pre-clinical	Active
MOTYS™	Doron Therapeutics	Phase 3	Active
Osteoarthritis Treatment Program	Biovico	Pre-clinical	Active
aGF	Scarcell Therapeutics	Phase 1	Active
Cartilage Repair	Sayenza Biosciences	Clinical	Active
BRM521	BRIM Biotechnology	Preclinical	Active